Ключевые слова:
атеросклероз, липопротеиды, рецепторы ЛПНП, LOX-1.Библиографические ссылки
Азизова Д.М., Мавлянов И.Р., Р.А. Сабирова, М.У. Кулманова, А.Б. Солиев, Г.Ж. Жарылкасынова. Разработка новых подходов к коррекции гиперлипидемии с учетом изменения жирнокислотного состава сыворотки крови // Анализ риска здоровью. – 2020. – № 2. – С. 152–163. DOI: 10.21668/health.risk/2020.2.17
Азизова Д.М., Сабирова Р.А., Кулманова М.У.Влияние БАД «Биомайса»на атерогенный индекс плазмы при развитии экспериментальной гиперхолестеринемии «Медицинские новости» Белорусь №7 (298) 2019 С.78-80
Гусев Е.Ю., Н.В. Зотова, Ю.А. Журавлева, В.А. Черешнев «Физиологическая и патогенетическая роль рецепторов-мусорщиков у человека» // Медицинская иммунология, 2020. Т. 22, № 1. С. 7-48. doi: 10.15789/1563-0625-PAP-1893.
Borén J., Chapman M.J., Krauss R.M., Packard C.J., Bentzon J.F., Binder C.J., Daemen M.J., Demer L.L., Hegele R.A., Nicholls S.J., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2020; 41:2313–2330. doi: 10.1093/eurheartj/ehz 962.
Canton J., Neculai D., Grinstein S. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol., 2013, Vol. 13, no. 9, pp. 621-634,
Chen M., Kakutani M., Minami M., Kataoka H., Kume N., Narumiya S., Kita T., Masaki T., Sawamura T. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arter. Thromb. Vasc. Biol. 2000; 20:1107–1115.
Chen M., Nagase M., Fujita T., Narumiya S., Masaki T., Sawamura T. Diabetes Enhances Lectin-like Oxidized LDL Receptor-1 (LOX-1) Expression in the Vascular Endothelium: Possible Role of LOX-1 Ligand and AGE. Biochem. Biophys. Res. Commun. 2001; 287:962–968. doi: 10.1006/bbrc.2001. 5674.
D’Agostino RB, Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117:743–753.
de Siqueira J., Abdul Zani I., Russell D.A., Wheatcroft S.B., Ponnambalam S., Homer-Vanniasinkam S. Clinical and preclinical use of LOX-1-specific antibodies in diagnostics and therapeutics. J. Cardiovasc. Transl. Res., 2015, Vol. 8, no. 8, pp. 458-465.
Goyal T., Mitra S., Khaidakov M., Wang X., Singla S., Ding Z., Liu S., Mehta J.L. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr. Atheroscler. Rep., 2012, Vol. 14, pp. 150-159.
Groen AK, Bloks VW, Verkade H, Kuipers F. Cross-talk between liver and intestine in control of cholesterol and energy homeostasis. Mol Aspects Med. 2014 Jun; 37:77-88.
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001 May 11;292(5519):1160-4.
Kattoor AJ, Goel A, Mehta JL. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants (Basel). 2019 Jul 11;8(7):218. doi: 10.3390/antiox8070218. PMID: 31336709; PMCID: PMC6680802.
Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet Needs in LDL-C Lowering: When Statins Won't Do! Drugs. 2016 Aug;76(12):1175-90. doi: 10.1007/s40265-016-0613-0. PMID: 27456066; PMCID: PMC4974266.
Valanti EK, Dalakoura-Karagkouni K, Sanoudou D. Current and Emerging Reconstituted HDL-apoAI and HDL-apoE Approaches to Treat Atherosclerosis. J Pers Med. 2018 Oct 03;8(4)
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020 Apr;21(4):225-245.
Hassan AB, Hozayen RF, Alotaibi RA, Tayem YI. Therapeutic and maintenance regimens of vitamin D3 supplementation in healthy adults: A systematic review. Cell Mol Biol (Noisy-le-grand). 2018 Nov 30;64(14):8-14.
Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic sur-vey. Athero-sclerosis. 2019 May; 284:129-135.
Mehta J.L., Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J. Am. Coll. Cardiol., 2002, Vol. 39, no. 9, pp. 1429-1435.
Nagase M., Hirose S., Sawamura T., Masaki T., Fujita T. Enhanced Expression of Endothelial Oxidized Low-Density Lipoprotein Receptor (LOX-1) in Hypertensive Rats. Biochem. Biophys. Res. Commun. 1997; 237:496–498.
Ouimet M, Barrett TJ, Fisher EA. HDL and Reverse Cholesterol Transport. Circ Res. 2019 May 10;124(10):1505-1518.
Pirillo A., Norata G.D., Catapano A.L. LOX-1, OxLDL, and atherosclerosis. Mediat. Inflamm. 2013; 2013 doi: 10.1155/2013/152786. [
Plat J, Baumgartner S, Vanmierlo T, Lütjohann D, Calkins KL, Burrin DG, Guthrie G, Thijs C, Te Velde AA, Vreugdenhil ACE, Sverdlov R, Garssen J, Wouters K, Trautwein EA, Wolfs TG, van Gorp C, Mulder MT, Riksen NP, Groen AK, Mensink RP. Plant-based sterols and stanols in health & disease: "Consequences of human development in a plant-based environment?". Prog Lipid Res. 2019 Apr; 74:87-102.
Qian L., Li X., Fang R., Wang Z., Xu Y., Zhang H., Bai H., Yang Q., Zhu X., Ben J., Xu Y., Chen Q. Class A scavenger receptor deficiency augments angiotensin II-induced vascular remodeling. Biochem. Pharmacol., 2014, Vol. 90, no. 3, pp. 254-264.
Rahmati-Ahmadabad S, Broom DR, Ghan-bari-Niaki A, Shirvani H. Effects of exercise on reverse cholesterol transport: A systemized narrative review of animal studies. Life Sci. 2019 May 01; 224:139-148.
Zani I.A., Stephen S.L., Mughal N.A., Russell D., Homer-Vanniasinkam S., Wheatcroft S.B., Ponnambalam S. Scavenger receptor structure and function in health and disease. Cells, 2015, Vol. 4, no. 2, pp. 178-201.
Zimmerman MP. How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control? Am Health Drug Benefits. 2015 Nov;8(8):436-42. PMID: 26702335; PMCID: PMC468 4634.
Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guide-lines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014; 311: 1416–1423. doi: 10.1001/ jama. 2014. 2632.
Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol. 2015; 26:1173–1180. doi: 10.1681/ASN.2014040400.
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289:1681–1690. doi: 10.1001/jama.289.13.1681.
Pothineni NVK, Karathanasis SK, Ding Z, Arulandu A, Varughese KI, Mehta JL. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. J Am Coll Cardiol. 2017 Jun 6; 69(22):2759-2768. doi: 10.1016/j.jacc.2017.04. 010. PMID: 28571642.].
Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci. 2013 Aug; 70(16): 2859-72. doi: 10.1007/s00018-012-11 94-z. Epub 2012 Nov 3. PMID: 23124189; PMCID: PMC4142049.
Kakutani M, Masaki T, Sawamura T. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):360-4. doi: 10.1073/pnas.97.1.360. PMID: 10618423; PMCID: PMC26668.
Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000 Mar;89(3):160-7. doi: 10.1007/pl00007320. PMID: 10798271.